RxDoctor Payments Data

James Holloway, MD

Internal Medicine · Deadwood, SDNPI 1346243813

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 97.0% of the total across 26 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 15 manufacturers, the largest accounting for just 18.0% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $263 and has fallen 85.3% since, to $39 in 2025.

$433in general payments, 2019–2025

Across 26 payments — averaging $16.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$78
  • Smith+Nephew$52
  • CSL Behring$44
  • Inspire Medical Systems, Inc.$39
  • Pharming Healthcare, Inc.$37
  • Atricure, Inc.$32
  • plus $151 from 9 others

What the payments were for

  • Food & beverage$42097%
  • Education$133%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$433 in reported general payments places this provider in the 80th percentile of 178 internal medicine providers in South Dakota.

See all internal medicine providers in South Dakota

Medicare billing

Part B allowed, 2024
$15,581
Medicare patients
282
Services billed
482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban68$67,641
JardianceEmpagliflozin47$40,474
OzempicSemaglutide34$33,393
MounjaroTirzepatide26$26,299
XareltoRivaroxaban19$24,566
AbrysvoRsv Vacc, Pref A And Pref B/Pf26$7,774
Metoprolol Succinate161$2,991
Potassium Chloride85$2,718
Ezetimibe32$2,582
ShingrixVaricella-Zoster Ge/As01b/Pf12$2,446
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,198
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen50$1,952
Atorvastatin Calcium257$1,525
Levothyroxine Sodium154$1,518
Omeprazole156$1,402

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$21$75,41594 claims
Boehringer IngelheimJardiance$17$40,47447 claims
Novo NordiskOzempic$78$33,39334 claims
Johnson & JohnsonXarelto$12$24,56619 claims
GSKShingrix$11$2,44612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 178 internal medicine providers in South Dakota.

Other internal medicine in Deadwood

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →